Naltrexone

Home
About
Help
History (1)
- Naltrexone
- See All Pages

"Naltrexone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.

Descriptor ID	D009271
MeSH Number(s)	D03.132.577.249.706.550 D03.605.497.750.550 D03.633.400.686.750.550 D04.615.723.795.706.550
Concept/Terms	Naltrexone Naltrexone Celupan Celupan Trexan Trexan Naltrexone Hydrochloride Naltrexone Hydrochloride Hydrochloride, Naltrexone ReVia ReVia Nemexin Nalorex Antaxone Antaxone EN-1639A EN-1639A EN 1639A EN1639A

Below are MeSH descriptors whose meaning is more general than "Naltrexone".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Alkaloids [D03.132]
Opiate Alkaloids [D03.132.577]
Morphinans [D03.132.577.249]
Naloxone [D03.132.577.249.706]
Naltrexone [D03.132.577.249.706.550]
Heterocyclic Compounds, Bridged-Ring [D03.605]
Morphinans [D03.605.497]
Naloxone [D03.605.497.750]
Naltrexone [D03.605.497.750.550]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 4 or More Rings [D03.633.400]
Morphinans [D03.633.400.686]
Naloxone [D03.633.400.686.750]
Naltrexone [D03.633.400.686.750.550]
Polycyclic Compounds [D04]
Polycyclic Aromatic Hydrocarbons [D04.615]
Phenanthrenes [D04.615.723]
Morphinans [D04.615.723.795]
Naloxone [D04.615.723.795.706]
Naltrexone [D04.615.723.795.706.550]

Below are MeSH descriptors whose meaning is related to "Naltrexone".

Below are MeSH descriptors whose meaning is more specific than "Naltrexone".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Naltrexone" by people in this website by year, and whether "Naltrexone" was a major or minor topic of these publications.

Bar chart showing 39 publications over 16 distinct years, with a maximum of 11 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
2007	0	1	1
2008	1	1	2
2009	0	1	1
2010	0	1	1
2011	1	1	2
2012	3	0	3
2013	2	0	2
2014	2	1	3
2015	1	0	1
2016	1	1	2
2017	9	2	11
2018	3	2	5
2019	1	0	1
2020	0	2	2
2021	0	1	1

Below are the most recent publications written about "Naltrexone" by people in Profiles.

Shirk SD, Ameral V, Kraus SW, Houchins J, Kelly M, Pugh K, Reilly E, Desai N. Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review. J Dual Diagn. 2021 Jul-Sep; 17(3):207-215.

View in: PubMed
Larochelle MR, Wakeman SE, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM. Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder: A Cohort Study. Med Care. 2020 10; 58(10):919-926.

View in: PubMed
Pivovarova E, Min HS, Friedmann PD. Impact of extended release naltrexone on health-related quality of life in individuals with legal involvement and opioid use disorders. Subst Abus. 2021; 42(4):618-624.

View in: PubMed
Walley AY, Lodi S, Li Y, Bernson D, Babakhanlou-Chase H, Land T, Larochelle MR. Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis. Addiction. 2020 08; 115(8):1496-1508.

View in: PubMed
Bagley SM, Larochelle MR, Xuan Z, Wang N, Patel A, Bernson D, Silverstein M, Hadland SE, Land T, Samet JH, Walley AY. Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose. Ann Emerg Med. 2020 01; 75(1):29-38.

View in: PubMed
Bradley ES, Liss D, Carreiro SP, Brush DE, Babu K. Potential uses of naltrexone in emergency department patients with opioid use disorder. Clin Toxicol (Phila). 2019 Sep; 57(9):753-759.

View in: PubMed
Soares WE, Wilson D, Gordon MS, Lee JD, Nunes EV, O'Brien CP, Shroff M, Friedmann PD. Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual. Drug Alcohol Depend. 2019 01 01; 194:482-486.

View in: PubMed
Finlay AK, Binswanger IA, Timko C, Smelson D, Stimmel MA, Yu M, Bowe T, Harris AHS. Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science. J Subst Abuse Treat. 2018 12; 95:43-47.

View in: PubMed
Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. Ann Intern Med. 2018 08 07; 169(3):137-145.

View in: PubMed
Williams AR, Nunes EV, Bisaga A, Pincus HA, Johnson KA, Campbell AN, Remien RH, Crystal S, Friedmann PD, Levin FR, Olfson M. Developing an opioid use disorder treatment cascade: A review of quality measures. J Subst Abuse Treat. 2018 08; 91:57-68.

View in: PubMed

People

Explore

Similar Concepts

Top Journals